The β<sub>2</sub>-adrenergic biased agonist nebivolol inhibits the development of Th17 and the response of memory Th17 cells in an NF-κB-dependent manner.

Front Immunol · 2024 · PMC11496295 · PMID 39445009

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

Nebivolol exhibited a decreasing trend in the proportion of IFN-γ + , an increasing trend in the proportion of IL-4 + , and a significant decrease in the proportion of IL-17A + memory Th cells ( Figures 3E–G ).

also in 47,180 other papers

showed a trendno p-value reported

Nebivolol had a trend of decreasing IFN-γ, showed a trend of increasing IL-4, and significantly decreased IL-17A when compared to the control group without treatment and the vehicle control ( Figures 1A–C ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.